Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA national ad campaign

Executive Summary

Board of directors authorizes 1995 campaign at its Dec. 8 meeting in New York City. The fourth year of the campaign will feature "HealthMatters" booklets on steps to prevent or detect diseases and on research into potential therapeutics. The first three specific diseases to be addressed are heart attacks, breast cancer and stroke: the heart attack booklet is scheduled for release in February. The booklets will be distributed, in part, as inserts in Newsweek, Reader's Digest and Time, with ads about the booklets in U.S. News, Smithsonian, Scientific American, The New York Times Magazine and New Yorker. TV ads announcing the availability of the brochures will appear on CNN and other national cable networks, PhRMA says. The board also votes to continue the "Inside the Beltway" (Washington, D.C. area) newspaper issues ads, which have been appearing since 1988. La Neil Gregory has been promoted to VP-advertising to head the advertising effort
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel